James Abell
Partner and CFO

has more than 10 years of venture capital experience and three years of operational experience in life science companies. His directorships have included Chroma Therapeutics, Clinical Designs and Syntaxin. He joined Abingworth as CFO in 1998, prior to which he was CFO of Prolifix from 1995 to 1998. He trained and qualified as a Chartered Accountant with KPMG. He holds a degree in Biology with Chemistry from the University of Southampton. James handles Abingworth’s finance and administration as well as investment matters, focusing on start-up companies.